As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
12 Analysts have issued a CureVac N.V. forecast:
12 Analysts have issued a CureVac N.V. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 83 83 |
87%
87%
|
|
| Gross Profit | 77 77 |
83%
83%
|
|
| EBITDA | 197 197 |
10%
10%
|
|
| EBIT (Operating Income) EBIT | 176 176 |
13%
13%
|
|
| Net Profit | 151 151 |
19%
19%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
| Head office | Netherlands |
| CEO | Alexander Zehnder |
| Employees | 904 |
| Founded | 2020 |
| Website | www.curevac.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


